Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 28 of 28 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
EML4 - ALK ALK V1180L	large cell neuroendocrine carcinoma	predicted - resistant		Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK V1180L was identified on post-progression biopsy in a patient with large cell neuroendocrine lung carcinoma harboring EML4-ALK (e20:e20), who previously responded to Alecensa (alectinib) treatment (PMID: 36207130).	36207130
EML4 - ALK ALK V1180L	lung adenocarcinoma	predicted - resistant		Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK V1180L was identified at progression on Alecensa (alectinib) in a patient with lung adenocarcinoma harboring EML4-ALK (PMID: 34058070).	34058070
EML4 - ALK ALK V1180L	lung small cell carcinoma	predicted - sensitive	Lorlatinib	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical case study, Lorbrena (lorlatinib) treatment resulted in tumor shrinkage after 5 months, with decrease in the size of intracranial and pulmonary lesions, in a patient with transformed small cell lung cancer from lung adenocarcinoma harboring EML4-ALK and ALK V1180L (PMID: 37907052).	37907052
EML4 - ALK ALK V1180L	lung adenocarcinoma	predicted - resistant		Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK V1180L was identified in the post-progression biopsy of a patient with metastatic lung adenocarcinoma harboring EML4-ALK who progressed on treatment with Alecensa (alectinib) (PMID: 37907052).	37907052
EML4 - ALK ALK V1180L	lung cancer	predicted - sensitive	Lorlatinib	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical case study, Lorbrena (lorlatinib) treatment resulted in a partial response lasting 20 months in a patient with lung cancer harboring EML4-ALK with ALK V1180L (PMID: 39363320; NCT02517892).	39363320
EML4 - ALK ALK V1180L	lung adenocarcinoma	predicted - sensitive	Ceritinib	Ceritinib	Case Reports/Case Series	Actionable	In a retrospective analysis, Zykadia (ceritinib) treatment resulted in a partial response with a progression-free survival of 7.3 months, overall survival of 26.3 months, and a duration of treatment of 8.2 months in a patient with lung adenocarcinoma harboring EML4-ALK (e6:e20) with ALK V1180L (PMID: 39500140).	39500140
EML4 - ALK ALK V1180L	lung non-small cell carcinoma	sensitive	Lorlatinib	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorbrena (lorlatinib) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis of non-small cell lung carcinoma cells harboring ALK V1180L in the context of EML4-ALK in culture (PMID: 26144315).	26144315
EML4 - ALK ALK V1180L	lung non-small cell carcinoma	resistant		Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).	25228534
EML4 - ALK ALK V1180L	lung non-small cell carcinoma	resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human non-small cell lung cancer cell line harboring ALK V1180L in the context of EML4-ALK was resistant to Xalkori (crizotinib) treatment in culture (PMID: 25228534).	25228534
EML4 - ALK ALK V1180L	Advanced Solid Tumor	resistant		Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).	25228534
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive	TAE684	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing ALK V1180L in the context of EML4-ALK in culture (PMID: 25228534).	25228534
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive	Ceritinib	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).	25228534
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).	25228534
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive	ASP3026	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).	25228534
EML4 - ALK ALK V1180L	Advanced Solid Tumor	resistant		Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK V1180L were resistant to Alecensa (alectinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited viability of transformed cells expressing EML4-ALK with ALK V1180L in culture (PMID: 33627640).	33627640
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive	Ceritinib	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited viability of transformed cells expressing EML4-ALK with ALK V1180L in culture (PMID: 33627640).	33627640
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited viability of transformed cells expressing EML4-ALK with ALK V1180L in culture (PMID: 33627640).	33627640
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive	Lorlatinib	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorbrena (lorlatinib) inhibited viability of transformed cells expressing EML4-ALK with ALK V1180L in culture (PMID: 33627640).	33627640
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive		Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Rozlytrek (entrectinib) inhibited viability of transformed cells expressing EML4-ALK with ALK V1180L in culture (PMID: 33627640).	33627640
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive		Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited viability of transformed cells expressing EML4-ALK with ALK V1180L in culture (PMID: 33627640).	33627640
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive		Iruplinalkib	Preclinical - Cell culture	Actionable	In a preclinical study, Iruplinalkib (WX-0593) treatment inhibited viability of transformed cells expressing EML4-ALK with ALK V1180L in culture (PMID: 35421578).	35421578
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) treatment inhibited viability of transformed cells expressing EML4-ALK with ALK V1180L in culture (PMID: 35421578).	35421578
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive		Ensartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ensacove (ensartinib) inhibited viability of a cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 31446141).	31446141
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive	Ceritinib	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited viability of a cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 31446141).	31446141
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited viability of a cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 31446141).	31446141
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive	Lorlatinib	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorbrena (lorlatinib) inhibited viability of a cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 31446141).	31446141
EML4 - ALK ALK V1180L	Advanced Solid Tumor	sensitive		NVL-655	Preclinical - Cell culture	Actionable	In a preclinical study, NVL-655 inhibited viability of cells expressing EML4-ALK and ALK V1180L in culture (PMID: 39269178).	39269178

Showing 1 to 28 of 28 entries

Filter rows:

Profile Name	EML4 - ALK ALK V1180L
Gene Variant Detail	ALK V1180L (unknown) EML4 - ALK (gain of function)
Relevant Treatment Approaches	ASP3026 Brigatinib Ceritinib Lorlatinib TAE684

Molecular Profile Detail

Contact

Filtering

Sorting